IBDEI393 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54628,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,54628,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,54629,0)
 ;;=E83.51^^256^2767^28
 ;;^UTILITY(U,$J,358.3,54629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54629,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,54629,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,54629,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,54630,0)
 ;;=E83.52^^256^2767^26
 ;;^UTILITY(U,$J,358.3,54630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54630,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,54630,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,54630,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,54631,0)
 ;;=E87.5^^256^2767^27
 ;;^UTILITY(U,$J,358.3,54631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54631,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,54631,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,54631,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,54632,0)
 ;;=E89.2^^256^2767^48
 ;;^UTILITY(U,$J,358.3,54632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54632,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,54632,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,54632,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,54633,0)
 ;;=E89.6^^256^2767^47
 ;;^UTILITY(U,$J,358.3,54633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54633,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,54633,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,54633,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,54634,0)
 ;;=L68.0^^256^2767^25
 ;;^UTILITY(U,$J,358.3,54634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54634,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,54634,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,54634,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,54635,0)
 ;;=M80.00XA^^256^2767^2
 ;;^UTILITY(U,$J,358.3,54635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54635,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,54635,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,54635,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,54636,0)
 ;;=M81.0^^256^2767^3
 ;;^UTILITY(U,$J,358.3,54636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54636,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,54636,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,54636,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,54637,0)
 ;;=M85.80^^256^2767^44
 ;;^UTILITY(U,$J,358.3,54637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54637,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,54637,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,54637,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,54638,0)
 ;;=N62.^^256^2767^24
 ;;^UTILITY(U,$J,358.3,54638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54638,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,54638,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,54638,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,54639,0)
 ;;=E10.43^^256^2767^6
 ;;^UTILITY(U,$J,358.3,54639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54639,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,54639,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,54639,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,54640,0)
 ;;=E10.59^^256^2767^4
 ;;^UTILITY(U,$J,358.3,54640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54640,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,54640,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,54640,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,54641,0)
 ;;=E10.618^^256^2767^5
 ;;^UTILITY(U,$J,358.3,54641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54641,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,54641,1,4,0)
 ;;=4^E10.618
